Use of cannabinoids in the treatment of epilepsy
AssigneeGW Research Limited
InventorsGeoffrey Guy, Stephen Wright, Orrin Devinsky
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Claims26
A method of treating seizures associated with a type of treatment-resistant epilepsy, which is Dravet syndrome, in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a cannabidiol (CBD) drug substance, wherein the CBD drug substance comprises at least 98% w/w CBD, and the remainder of the drug substance comprises (i) not more than 0.15% w/w cannabidiolic acid (CBDA), (ii) not more than 1.0% w/w cannabidivarin (CBDV), (iii) not more than 0.15% w/w delta-9 tetrahydrocannabinol (Δ9THC), or (iv) not more than 0.5% w/w cannabidiol-C4 (CBD-C4);
- and
- wherein the dose of CBD administered to the patient ranges from about 5 mg/kg/day to about 25 mg/kg/day.
Dependencies are inferred from the claim text.